Results

1–10 of 35 results for Bevacizumab

Intracameral Delivery of Bevacizumab in the Management of Anterior Segment Recalcitrant Neovascular Complications of Proliferative Vascular Retinopathies
Marib I Akanda, MD
Annual Meeting Talks
2025
Lower Socioeconomic Status Is Associated With Increased Bevacizumab Use Among Patients Initiating Anti-VEGF Therapy for Diabetic Macular Edema
Judy E. Kim, MD, FASRS
Annual Meeting Talks
2025
Analysis of Antivascular Endothelial Growth Factor Utilization Trends and Prescriber Characteristics Based on Medicare Part B Claims Data: 2017-2022
Stephanie B Engelhard, MD
Annual Meeting Talks
2025
Evaluating Clinical Signs of Regression in Eyes Treated With Intravitreal Bevacizumab for Type 1 Retinopathy of Prematurity
Yuxi Zheng, MD
Annual Meeting Talks
2025
Evaluating the Visual, Anatomic, and Treatment Effects of Switching from Higher-cost Anti-VEGF to Lower-cost Bevacizumab After Loss of Copay Assistance (Good Days) Funding in Neovascular Age-Related Macular Degeneration
Jesse J Jung, MD, FASRS
Updates from the Field
2026
Quantifying Laser Burn Spots to Peripheral Avascular Retina Post-Bevacizumab Treatment in Retinopathy of Prematurity Infants at Different Age Groups
Swati Agarwal-Sinha, MD, FASRS
Annual Meeting Talks
2023
Bevacizumab-First vs Real-World Cost Outcomes for Diabetic Macular Edema: 2-Year Cost Analysis Modeled on DRCR Protocol AC Results
Dilraj S Grewal, MD, FASRS
Annual Meeting Talks
2023
Impact and Outcomes of Anti-VEGF Prior Authorization Requests: Insights From a Large Database Analysis
Saira Khanna, MD
Annual Meeting Talks
2023
Cost-Effectiveness of Aflibercept Monotherapy vs Bevacizumab-First Followed by Switching to Aflibercept if Needed for Diabetic Macular Edema
Mathew W. MacCumber, MD, PhD
Annual Meeting Talks
2023
Subretinal Aflibercept vs Ranibizumab vs Bevacizumab in the Context of PPV: Pneumatic Displacement With Subretinal Air and tPA in Naïve Submacular Hemorrhage Due to nAMD
Matias Iglicki, MD
Annual Meeting Talks
2024